Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Atractylodes macrocephala Koidz. extract promotes anagen entry and hair regrowth by enhancing dermal papilla cell activity and supporting hair cycle progression in a mouse model.

This review discusses biotin and biotinidase deficiencies, their symptoms, and methods of medical management, without presenting new clinical findings.

This study found that AR/VDR-targeted agonist hormone therapy can inhibit cell viability in HR2-av triple-negative breast cancer cell lines through multiple mechanisms and may enhance the effects of chemotherapy.

This article discusses arsenic trioxide as a treatment for refractory or relapsed acute promyelocytic leukemia, noting its effectiveness and manageable side effects.

This case report details a patient with myasthenia gravis and a malignant thymoma whose rising liver function tests, initially thought to be related to antibiotic use, were ultimately attributed to thymoma-associated multiorgan autoimmunity.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.

In this case series, dual-targeted therapy was observed to provide promising clinical responses in refractory inflammatory bowel disease, with 88.23% to 100% response rates across 9 months and an endoscopic response in 88.89% of evaluated patients, though some adverse events occurred.

In this study, optical coherence tomography detected hair follicles at the dermoepidermal junction not visible on the scalp surface in alopecia areata patients, suggesting OCT may help monitor treatment response.

This study introduced a Density-Calibrated Airtouch Protocol (DCAP) that suggests customizing the Airtouch hair coloring technique based on client hair density to optimize color blend, pigment longevity, and hair health.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

This review discusses the use of trichoscopy for diagnosing alopecia and reports no new clinical results, emphasizing its role in identifying vascular and follicular features.

This study found that in patients with alopecia areata, trichoscopy was a valuable tool for monitoring disease activity, severity, and therapeutic response, showing changes in trichoscopic markers that preceded improvements observed in the hair pull test.

This population-based study found a significant association between alopecia areata and autoimmune thyroid diseases, including Hashimoto's and Graves' disease, confirming a higher prevalence of these conditions in individuals with alopecia areata.

This study found that in patients with AIDS-related non-Hodgkin lymphoma undergoing targeted therapy, a positive serum albumin change rate was significantly associated with better treatment outcomes, suggesting the value of dynamic albumin monitoring and nutritional support during treatment.

This study suggests that observing the acute telogen effluvium triad—frontal fringe, temporal recess, and occipital fringe—can aid in diagnosing telogen effluvium during resolution phases, despite challenges like negative pull tests.

This review discusses biotinidase deficiency, noting that biotin treatment from birth can prevent symptoms, but acknowledges the complexity and need for further understanding due to late-onset cases with varied clinical findings.

This study reports two cases of severe alopecia areata showing seemingly permanent hair regrowth with a modified triamcinolone acetonide regimen involving epinephrine, and suggests a potential role for epinephrine in enhancing treatment efficacy.

Farudodstat may effectively treat alopecia areata without harmful side effects.

This study reports that adding androgen deprivation therapy to salvage radiation therapy for patients with non-metastatic biochemical recurrence of prostate cancer after radical prostatectomy improves progression-free survival, particularly in those with higher post-prostatectomy PSA levels.

In this research, the authors reported that long-term treatment with the JAK1/JAK2 inhibitor baricitinib effectively maintains hair regrowth in patients with severe alopecia areata and may gradually improve outcomes for partial responders over 104 weeks, without increasing side effect incidence.

This study developed a new neural network model (AA-GAN-AB-MTEDeep) to enhance Alopecia Areata classification using synthetic scalp images, achieving an accuracy of 96.94%.

Hydroxychloroquine effectively treated twenty-nail dystrophy in a patient with alopecia areata.

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

This study observes that TYK2 inhibition with BMS-986202 may extend hair follicle growth phases and decrease inflammatory cell markers in alopecia areata, suggesting potential for clinical application.

In this study of BPH patients with testosterone deficiency, the combination of TU and dutasteride reduced prostate volume and improved testosterone-related symptoms but was less effective for sexual function compared to TU alone, indicating caution in using dutasteride for those with sexual dysfunction concerns.

This entry contains no research abstract, so no scientific findings or conclusions are reported.

In this study, BTXA injections did not effectively treat recalcitrant alopecia areata or improve hair regrowth in most patients, suggesting its limitations as an alternative therapy.